Stocks Health care INO
NASDAQ · Health careInovio Pharmaceuticals, Inc. (INO)
Inovio Pharmaceuticals, Inc. brought in $0 of revenue over the twelve months to June 30, 2026, down 100.0% from a year earlier. It posted a net loss of $67.4M. In fiscal 2025 capital spending exceeded operating cash flow by $88.9M. At June 30, 2026 it held $31.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
What Inovio Pharmaceuticals, Inc. does
Inovio Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker INO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $65.3K | -$84.9M | -$1.81 | -$88.9M |
| 2024 | $217.8K | -$107.3M | -$3.95 | -$104.6M |
| 2023 | $832K | -$135.1M | -$6.09 | -$124.7M |
| 2022 | $10.3M | -$279.8M | -$14.07 | -$217.2M |
| 2021 | $1.8M | -$303.7M | -$17.45 | -$216.9M |
| 2020 | $7.4M | -$166.4M | -$12.88 | -$179.5M |
Latest SEC filings
What Inovio Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 12, 2026
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- July 31, 2026Passive stake (5% or more) SCHEDULE 13G
- July 31, 2026
- July 30, 2026
- July 29, 2026
- July 29, 2026
Questions about INO
What does Inovio Pharmaceuticals, Inc. do?
Inovio Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker INO.
Is Inovio Pharmaceuticals, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $67.4M.
How much revenue does Inovio Pharmaceuticals, Inc. make?
Over the twelve months to June 30, 2026 Inovio Pharmaceuticals, Inc. reported revenue of $0. That is 100.0% less than a year earlier.
When did Inovio Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026.
Similar companies
Follow INO
Get an email when Inovio Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow INO: get an email when it filesWhere the numbers come from
Financial figures are the values Inovio Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.